-
Cingulate Inc NasdaqCM:CING Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Location: 1901 West 47th Place, Kansas City, KS, 66205, United States | Website: https://www.cingulate.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
14.24M
Cash
9.519M
Avg Qtr Burn
-3.578M
Short % of Float
7.42%
Insider Ownership
2.40%
Institutional Own.
3.22%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
CTx-1301 (dexmethylphenidate) Details Attention deficit hyperactivity disorder | NDA Submission | |
CTx-1302 (dextroamphetamine) Details Attention deficit hyperactivity disorder | Phase 1/2 Initiation | |
CTx-2103 (buspirone) Details Anxiety Disorders | IND Submission |